Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral FT011 in diffuse systemic sclerosis
NL-OMON51103Phase 2Active, not recruiting
- Sponsor
- Certa Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asengeprast in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Certa Therapeutics. Primary endpoints: FT011 maximum concentration, Time to maximum concentration and 2 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
asengeprast
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NL-OMON51103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51103.